• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , March 9

Ranbaxy Laboratories Ltd has entered into a strategic alliance with Zenotech Laboratories, India, as per which, the former will market the latter's injectible oncology products under its own label. While initially, Ranbaxy will be marketing and distributing the products in the key markets of Latin America including Brazil and Mexico, Russia and other CIS markets, it is also exploring the possibility of expanding this collaboration to other markets.

Zenotech will develop and manufacture these oncology products at their dedicated facilities located in India.

In a statement, Mr Peter Burema, President, Europe, Africa, CIS and Latin America, Ranbaxy, said, the relationship with Zenotech will complement each other's strengths. The alliance facilitates Ranbaxy's entry into this new therapeutic segment in these key markets.

To expand market reach

Dr Jayaram Chigurupati, CEO of Zenotech Laboratories, added, "This collaboration will enable us to expand the market reach of our speciality injectibles portfolio to cancer patients in several emerging markets around the world. The alliance will positively impact Zenotech in speeding up its own biogenerics development programme."

Ranbaxy has a presence in the oncology segment in India and sells its product in the domestic market through its Super Specialties division. Zenotech is a specialty generic injectables company with a biotech core and is present in high value products serving niche therapy areas such as oncology, anaesthesiology, gynaecology, and neurology.

The share price of Ranbaxy closed at Rs 420.25 on the BSE, down 2.63 per cent.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Pepsi bottling plant in Vizag told not to use groundwater

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line